Clinical Trials

58 enrolled

Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

48 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Other hematologic neoplasm

300 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

32 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07128680 2026-05-11

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06800339 2026-05-06

NEORADJUVANT

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

75 enrolled

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT07075120 2026-04-30

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

15 enrolled

Carcinoma, Hepatocellular

NCT06889493 2026-04-28

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

36 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05187182 2026-04-27

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

42 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

60 enrolled

Carcinoma, Transitional Cell

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT07401875 2026-04-02

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Kidney Neoplasms

NCT05681780 2026-03-31

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05254184 2026-03-30

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

246 enrolled

Carcinoma, Hepatocellular

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

25 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

14 enrolled

Prostatic Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

36 enrolled

Melanoma

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT05234307 2026-02-06

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07376707 2026-01-29

TGI5

DermatologicGastrointestinalThoracic

194 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06968988 2026-01-08

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

18 enrolled

Sarcoma

NCT05802056 2025-12-19

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

15 enrolled

Stomach Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

56 enrolled

Fibrolamellar hepatocellular carcinoma

NCT05629546 2025-09-12

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

33 enrolled

Melanoma

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

BreastDermatologicGastrointestinalHead & NeckThoracic

40 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

50 enrolled

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT03690986 2025-07-23

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

12 enrolled

Melanoma, Skin Neoplasms

NCT04323046 2025-05-04

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

20 enrolled

CNS

Glioblastoma, Glioma

NCT05112549 2025-04-03

IT-PD1

46 enrolled

Meningeal Neoplasms

NCT06097975 2025-01-20

NEO-GLITIPNI

18 enrolled

CNS

Glioblastoma

NCT05266612 2024-08-09

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

12 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06274437 2024-08-07

A Study of BND-35 in Participants With Advanced Solid Tumors

280 enrolled

Tumor-Agnostic

Neoplasms

NCT04823403 2024-07-26

HIPANIV

27 enrolled

Carcinoma, Hepatocellular

NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

28 enrolled